Biocompatibles Limited

Abbott Laboratories Corporation

Biocompatibles UK Limited

Michael John Driver

Andrew Lennard Lewis

Peter William Stratford

Stephen A Jones

Roderick W Bowers

Peter W Straford

Sean Leo Willis

Richard Paul Redman

Jeremy Colin Russell

Vincent James O'Byrne

David Michael Grey

Samantha Ryan

Deborah Jane Jackson

Stephen Alister Jones

Vincent James Conor O'BYRNE

An intravascular stent has a coating comprising a crosslinked amphiphilic polymer and a sparingly water soluble matrix metalloproteinase inhibitor (MMPI). Preferably the polymer is formed from 2-methacryloyloxy-2'-ethyltrimethylammonium phosphate inner salt, Calkyl methacrylate and reactive and/or crosslinking monomer and the MMPI is a hydroxamic acid, more preferably batimastat. Preclinical and clinical results are reported, showing good luminal areas and reduced intimal thickening.

Drug delivery from stents

A method of producing an intravascular stent has a coat comprising a crosslinked amphiphilic polymer and a sparingly water soluble matrix metalloproteinase inhibitor (MMPI). Preferably the polymer is formed from 2-methacryloyloxy-2'-ethyltrimethylammonium phosphate inner salt, Calkyl methacrylate and reactive and/or crosslinking monomer and the MMPI is a hydroxamic acid, more preferably batimastat. Preclinical and clinical results are reported, showing good luminal areas and reduced intimal thickening.

A novel class of polymers obtainable by copolymerising a monomer mixture comprising (i) hydrophilic monomer of general formula (I) Y&#x2014;B&#x2014;X; (ii) styrene or a substituted styrene, a monomer or mixture of monomers which when polymerized form a polymer with a Tg lower than the Tg of a homopolymer of monomer (I) and lower than the Tg of a homopolymer of monomer (ii); and a monomer having a crosslinkable group is described. The invention also relates to a method for producing such polymers, implants coated with the polymers and methods for forming the same.

Polymer

An intravascular stent has a coat comprising a crosslinked amphiphilic polymer and a sparingly water soluble matrix metalloproteinase inhibitor (MMPI). Preferably the polymer is formed from 2-methacryloyloxy-2'-ethyltrimethylammonium phosphate inner salt, Calkyl methacrylate and reactive and/or crosslinking monomer and the MMPI is a hydroxamic acid, more preferably batimastat. Preclinical and clinical results are reported, showing good luminal areas and reduced intimal thickening.

Ethylenically unsaturated compounds

Phosphoric acid esters and their use in the preparation of biocompatible

##STR1## A process for treating suitable synthetic polymers comprising the steps of (a) where appropriate, activating the surface to be treated, and, if necessary, providing spacer groups thereon; and (b) treating the surface with a compound of formula (I), wherein Y' is an alkylene group optionally containing an aryl group, a poly(ethylene glycol) or a glycerol group; R may be the same or different and each is a straight or branched C.sub.1-4 alkyl group, n is from 1 to 4 and X is a group which reacts with functional groups of the polymer. Polymeric surfaces and materials thus produced and shaped articles containing such surfaces and materials.

Process for preparing organophosphates useful for increasing the ocular

Method of improving the ocular haemo and biocompatibility of synthetic

Method of reducing protein deposition in sight correction devices

Growing community of inventors

Surrey, United Kingdom

Michael John Driver